Ranbaxy Laboratories Ltd (RLL) has received approval in Canada to manufacture and market Ran - Lisinopril 5, 10 and 20 mg oral tablets from Health Canada, Therapeutic Products Directorate (TPD). Total brand market for Lisinopril 5, 10, and 20 mg oral tablets in Canada is CAD $46 mn.

Lisinopril is indicated for the treatment of hypertension and may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents, and as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis, as well as in the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival.

"We are pleased to receive this approval for RAN-Lisinopril to expand Ranbaxy's product portfolio of accessible generic product offerings. The product formulation was developed and data assembled by RLL. RAN-Lisinopril will be manufactured in Ranbaxy's cGMP facility located in North Brunswick, New Jersey. RPCI's Sales Team will be offering product to all classes of trade in all of the Canadian provinces immediately," said Paul Drake, president, Ranbaxy Pharmaceuticals - Canada Inc. (RPCI), Canada.

Ranbaxy Pharmaceuticals Inc (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of the RLL, India's largest pharmaceutical Company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.